Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial.

Kidney Med · 2023 · PMC9803830 · PMID 36593877

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

For central systolic pressures, the difference of 6.1 mm Hg between the study groups (95% CI: −0.11, 12.34; P = 0.05) was borderline significant.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.